Summary More research and new treatment options are needed in all stages of lung cancer. To this end immunotherapy needs a revival in view of recent improved technologies and greater understanding of the underlying biology.
). Small-cell lung cancer accounts for the remaining 2'0% of lung cancer and. despite displaying initial chemosensitivitv. cure is achieved in onlv a minonty of patients.
How can survival be improxved in lung cancer'? Different strategies have been employed to improve the outcome. Despite the suggested benefit of adjuvant chemotherapy (NSCLC Group. 1995) . the role of adjuvant therapy in operable disease awaits confirmation in large adjuvant trials. The value of preoperatixe (neoadjuvant) chemotherapy in NSCLC stage I. H and [Ila lung, cancer is currently the focus of large randomized trials. including, the MRC LU22 national study. The interest in this approach comes from the encouraging positive effect of this treatment in two randomized studies (Rosell et al. 1994 : Roth et al. 1994 (Thatcher et al. 1997 
TUMOUR IMMUNOLOGY
Cancer cells differ from normal cells both qualitatively and quantitativelv. These differences are due to abnormal alycosxlation of surface proteins. expression of viral. mutated or overexpressed oncogene products or differentiation anticens (Boon. 1997 : Wevnants. 1997 Miller (1979) Oral 308 No benefit McKneally (1981) Intrapleural 169 Improved survival (stage 1) Mountain (1981) Table 2. EL-2 used alone or in combination xxith other cvtokines or ly mphokine-actixated killer (LAK) cells in phase II trials in NSCLC has induced some responses (Table 3 ). In the Eastern Co-operative Oncologx group trials. IL-2 xxas used alone or with IFN'-P: only 3 out of 73 patients showed a response. x ith a median sunrixal of 35.6 w-eeks and no added adxantage xxith IFN-f (Kriegel et al. 1991). Lissoni et al (1994) Table 5 . These studies showed no statistically significant difference in time to progression or surnix al.
Randomized trials have examined the use of recombinant IFN-a as maintenance therapy following response to chemotherapy in SCLC (Table 6 ). All these studies shoxxed no surnixal improxement for the IFN arm except for one study by Mattson et al ( 1992) . In this study. 237 patients were randomized following chemotherapx and radiotherapy treatment to no treatment or maintenance treatment x ith lEN-ax. A (1996) Ifosfamide alone or ifosfamide followed by 22
No improvement in DFS or OS thymosin alpha and low dose IFN-a DFS. disease-free survival; OS, overall survival. (Takita et al. 1991 ). More recently. Carbone and his colleagues (Gabrilovich et al. 1997) have vaccinated lung cancer patients with peptides encoding mutated ras and p53 oncogene products. They are using the dendritic cell vaccination approach: dendritic cells are purified from cancer patients loaded with the specific peptide antigens and reinfused intravenously to the patient. The rational behind this approach is that dendritic cells are professional APCs. w%hich express high levels of co-stimulatorv molecules and HLA molecules and so an efficient T stimulation should follow after dendritic cell vaccination. ADOPTIVE IMMUNOTHERAPY Rosenberg et al (1986) . pioneered the use of tumour-infiltrating lymphocytes (TILs) and showed that adoptively transferred TILs exerted anti-tumour activity in patients with cancer. The ability of IL-2 to expand these cells in vitro made such an approach feasible. The initial few small trials that used adoptive immunotherapy alone or in combination wvith IL-2 in advanced lung cancer. demonstrated the feasibility of such an approach (Bemstein et al. 1989 : Kradin et al. 1989 : Faradji et al. 1991 ). A more recent study (Kimura et al. 1996) used adoptive immunotherapy in 82 patients British Joumal of Cancer (1998) 78(3), [282] [283] [284] [285] [286] [287] [288] following curative resection. The patients were randomized to receive IL-2 and LAKs following two courses of combination chemotherapy (cisplatin, vindesine and mitomycin) or chemotherapy alone. The 5-and 7-year survival rates of the chemo-immunotherapy group and chemotherapy group were 58.2% and 31.5% respectively in stage H and IIIA patients. This difference was statistically significant (P=0.0038). In patients undergoing non-curative resection, Kimura et al (1995) reported a survival benefit for the immunotherapy arm (IL-2 and LAK) following randomization of 105 patients to chemotherapy, radiotherapy or immunotherapy. The 7-year survival rate was greater in the immunotherapy group compared with the chemotherapy and chemo-radiotherapy groups (39.1%. 12.7%, P < 0.01).
FURTHER AVENUES FOR IMMUNOTHERAPY
The recent advances in tumour antigen characterization will encourage the development of more standardized anti-tumour vaccines. For example, the identification of a series of melanomaspecific gene products termed MAGEs has raised the hopes that similar specific antigens can be found in other tumours. Indeed. some of the MAGE antigens are expressed in about 40% of NSCLCs (Weynants et al, 1994) Another approach is to provide the TS/AA via irradiated wholecell tumour vaccines. A multitude of preclinical studies have shown that ex vivo transfection of cytokine genes [e.g. IL-2. granulocyte-macrophage colony-stimulating factor (GM-CSF)] and co-stimulatory molecule genes can augnent the immunogenicity of the cell vaccine in vivo. This is improved by gene combination. e.g. B7.J and IL-2 genes (Gaken et al. 1997) or GM-CSF and IL4 (Wakimoto et al, 1996) .
The IL-2 gene has been introduced into TILs via a retroviral vector to improve IL-2 delivery into the tumour. A recent phase I study used this approach in ten patients with advanced NSCLC with pleural effusion who showed some improvement in the pleural effusions (Tan et al. 1996) .
Targeting the tumour by in vivo gene therapy is another option that at present is only feasible by local intratumoral delivery. It is likely that in the next 10 years progress in gene delivery systems will allow in vivo gene targeting after i.v. injection of the vector. One option is to deliver genes coding for immunostimulatory molecules such as IL-2 (Tursz et al. 1996) . Another option is to correct genetic abnormalities in tumour cells. Roth et al. ( 1996) have delivered a retroviral vector containing the wild-type p53 gene directly into p53-mutated NSCLC tumours in nine patients with advanced disease. Wild type p53 regulates the progression of cells in the cell cycle from GI to the S-phase. Mutation ofp53 is usualy a late event in lung cancer and leads to uncontrolled growth of cancer cells. Reintroduction of the dominant wild-type (unmutated gene) can revert this process. Roth et al (1996) observed tumour regression and apoptosis in the tumours of some treated patients. Another option is to introduce a gene whose product converts a non-toxic pro-drug to a toxic compound. Herpes simplex virus thymidine kinase (HSV-TK) in combination with endogenous TK phosphorylates the pro-drug gancyclovir (GCV) to toxic gancyclovir triphosphate (GCV-PPP). Interestingly, GCV-PPP can enter untransfected neighbouring tumour cells through communicating gap junctions. and this leads to death of non-expressing HSV-TK cells (local bystander effect). This is important as only a small proportion (20%) of the cells in a tumour need to express HSV-TK to bring about 100% of tumour cell death. An inflammatory raction in response to the cell death with accumulation of type-I cytokines fiuther increases the bystander effect by boosting local and systemic immunological recognition of the tumour cells (Freeman et al. 1997) . Recently, this approach has been used in the treatment of pleural mesothelioma in rats. HSV-TK expressing adenoviral vectors were injected directly intrapleurally with significant reduction in tumour burden (Elshami et al. 1996) . Human studies are on-going (Treat et al. 1996) .
Another approach is to use anti-idiotypic antibodies. These antibodies are raised against monoclonal antibodies recognizing cellsurface tumour antigen and have a similar shape to the tumour antigen. This approach is currently the focus of an EORTC trial (SIILVA study) that uses an anti-idiotype BEC2 (anti-idiotype to ganglioside GD3) combined with BCG adjuvant in SCLC. A pilot study (Grant et al, 1996) 
